Key facts
- It has raised $30.0M; the latest was Early Stage VC ($30.0M) in Nov 2025.
- Notable investors include HOF Capital, Nat Friedman, Brian Armstrong, Joshua Kushner, SciFounders.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Preventive
- ·The full record, as it builds
Funding rounds
No funding rounds for Preventive are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Preventive
Developer of prenatal gene-editing technologies intended for the prevention of severe genetic conditions before birth. The company's platform utilizes advanced CRISPR and prime editing tools to conduct rigorous preclinical research on embryos, enabling the scientific and medical communities to evaluate whether correcting devastating hereditary mutations at the earliest stage of development can safely provide future children with a life free from progressive disease.
- Sector
- Healthcare
- HQ
- DE
- Founded
- 2025
- Employees
- 5
- Website
- preventive.bio/
- Ownership
- Privately Held (backing)
Preventive doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Preventive shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Preventive in its N-PORT filings yet. We sweep new filings monthly.